Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View

Author(s): D. O. Stichtenoth

Volume 4, Issue 6, 2004

Page: [617 - 624] Pages: 8

DOI: 10.2174/1389557043403783

Price: $65

Abstract

Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. In comparison to the first generation, they show an at least equivalent efficacy in the treatment of pain and inflammation. However, the postulated gain of safety is yet difficult to determine and seems to be, if any, small.

Keywords: safety, efficacy, pain, inflammation, valdecoxib, parecoxib, etoricoxib, lumiracoxib


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy